The report on “Global Alzheimer Prevalence and Drugs Demand” includes the overall market for the treatment of Alzheimer, performance of drugs by sales and market share. In terms of countries we have mentioned United States and China. US section talks about prevalence of the disease, overall market size by value further segmented into drugs market with present and historical performance also forecasting helps to analyse the future of the industry. In China section we have discussed a general overview of the disease, prevalence, causes and medicine market share. Industry trends section represents various factors accounting for any change in the treatment and new developments. Report also includes factors responsible for the treatment demand and development of new therapies in the driving forces section. The report also discusses competition prevailing in the present industry and overview of leading players business and business strategies.
Market is showing a constant growth rate largely driven by aging population but still there is no cure for the disease. The number of Americans with Alzheimer’s disease and other dementias will grow each year as the proportion of the U.S. population that is over age 65 continues to increase.
Three major primary medications on the market for Alzheimer disease - Aricept, Exelon, and Razadyne are AChE inhibitors, and the fourth medication, Namenda, is a NMDAr antagonist.
The global Alzheimer's disease treatment market was valued at USD8.3 billion in 2010. By geography, North America is heading the market with 37.73% share of the global Alzheimer market in 2010.
The leading markets for Alzheimer disease therapeutics were United States, Europe, and Japan accounting for a large share of the overall market.
The top 5 pharmaceutical companies in this market are Eisai, Forest Pharmaceutical, Novartis, Pfizer, and Johnson & Johnson.
In 2009, Namenda market share has reached to 20.94% from 20.63% in 2008. Namenda is covered by a U.S. method of use patent which was expected to expire in 2010 but now extended to 2015.
Aricept accounted for the royal share of the market (32.34%), Exelon and razadyne accounted for 7.85% and 5.62% market share in 2009.
In US, Aricept is the market leader with 62.61% share in 2010 as compared to 53.90% in 2009. Demand has been slowed in recent past years also contribution of other players and expiry of some of the patents affected the sales in US.
The mental disorder treatment is driving Chinese psychiatric drug market which represented USD250 million in 2007 and now it is expected to reach to USD1.2 billion in 2013.
Huperzine A (Chinese brands) and donepezil (Eisai's Aricept, Chinese brands) are two leading drugs dominating the treatment of Alzheimer's disease and the overall Alzheimer's disease market in China constituted around USD17.74 million in 2009.
The AD market could cross USD9.0 billion by 2016 with the introduction of disease-modifying drugs (DMDs). AD is likely to be the primary driver of growth in the larger central nervous system market from 2005 to 2011, expected to grow with a compound annual growth rate (CAGR) of 1.21%
Scope of the Report
The report gives a detailed analysis of the Global Alzheimer prevalence and drugs demand with discussion of industries past performance, present analyses and future outlook of the industry.
We have discussed US Alzheimer prevalence and overall market in detail, further segmented by drugs, market share and market value.
US Alzheimer drugs section will help the various medical companies worldwide to measure the potential of the market in the region and introduce drugs which may slow down the effect of the disease.
Industry trends provide opportunities prevailing and potential market wherein a persisting demand exists for curing the disease.
We have discusses industry players positioning, profiled major players and further scope for new and existing players.
Present report may help present and new players seeking to enter into new geographies and looking for new prospects and formulate strategies.
Forecasting plays an important part in the report which directs market players to build up strategies and shows industry scope.